Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort
PLOS ONE · 08.01.2025 · 20 (1) · e0313338
DOI: 10.1371/journal.pone.0313338 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS ONE, online erschienen am 08.01.2025. Verfasst von Yoshiyuki Yokomaku und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan. Hauptthemen laut MEDLINE: HIV Infections, Emtricitabine, Tenofovir, Anti-HIV Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
BICSTaR (BICtegravir Single Tablet Regimen) is an ongoing, observational cohort study assessing the virologic effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) and treatment-naïve (TN) people with HIV across 14 countries over 24 months. We present 12-month outcomes from participants in the BICSTaR Japan cohort. Retrospective and prospective data were pooled from people with HIV aged ≥20 years receiving B/F/TAF within routine clinical care in Japan. Outcomes included virologic effectiveness (primary endpoint; HIV-1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
- AIDS Medical Center, NHO Osaka National Hospital, Osaka, Japan.
- Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
- Internal Medicine, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan.
- Medical Affairs-HIV, Gilead Sciences K.K., Tokyo, Japan.
ORCID-Profile: Yoshiyuki Yokomaku, Takuma Shirasaka
Förderung
- Gilead Sciences
Zitieren
APA
Yokomaku, Y., Teruya, K., Watanabe, D., Endo, T., Minami, R., Taguchi, N., Cassidy, T., Marongiu, A., Thorpe, D., Shirasaka, T., & Oka, S. (2025). Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort. PLOS ONE, 20(1), e0313338. https://doi.org/10.1371/journal.pone.0313338
Vancouver
Yokomaku Y, Teruya K, Watanabe D, Endo T, Minami R, Taguchi N, et al. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort. PLOS ONE. 2025;20(1):e0313338. doi:10.1371/journal.pone.0313338
BibTeX
@article{Yokomaku2025,
author = {Yokomaku, Yoshiyuki and Teruya, Katsuji and Watanabe, Dai and Endo, Tomoyuki and Minami, Rumi and Taguchi, Nao and Cassidy, Tali and Marongiu, Andrea and Thorpe, David and Shirasaka, Takuma and Oka, Shinichi},
title = {Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort},
journal = {PLOS ONE},
year = {2025},
volume = {20},
number = {1},
pages = {e0313338},
doi = {10.1371/journal.pone.0313338}
}
EUVIMED